European drug regulators are weighing whether the benefits of testosterone replacement therapy are worth the risk of life threatening cardiovascular events. Testosterone therapy, such as AbbVie’s AndroGel, is approved in both the United States and Europe for the treatment of hypogondaism, a condition in which the body does not produce enough testosterone. This can cause symptoms such as low sex drive and muscle loss. In recent years, makers of testosterone treatments have heavily marketed the drugs directly to consumers, asking men if they suffer from what they deem symptoms of “Low-T” – weight gain, fatigue, and general grumpiness. The campaign was ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.